Hester Biosciences Ltd (HESTERBIO) — shareholding pattern, promoter holding, financials and share price
About Hester Biosciences Ltd (HESTERBIO)
Hester Biosciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as HESTERBIO and on the BSE under scrip code 524669. Its ISIN is INE782E01017.
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines. [1]
Hester Biosciences Limited is a leading animal healthcare company in India, specializing in poultry and large animal vaccines. Its strategic focus on biotechnology is highlighted by the recent approval of the H9N2 Avian Influenza vaccine, expanding its poultry vaccine portfolio. The company has successfully doubled its drug product capacity with the new fill/finish facility, supporting increased manufacturing capabilities. Hester's strategic shift aims to reduce dependence on tender-driven revenues, focusing on direct engagement with commercial markets. The company continues to invest in operational discipline, resulting in substantial improvements in profitability.
Listed peers in Pharmaceuticals: NGL Fine Chem Ltd, Sakar Healthcare Ltd, Windlas Biotech Ltd, Amrutanjan Health Care Ltd, Jagsonpal Pharmaceuticals Ltd, Shukra Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹2,109.4 a share on 10 Jul 2026, Hester Biosciences Ltd (HESTERBIO) was valued at a price-to-earnings ratio of 31.21x against an industry P/E of 36.41x and a price-to-book of 4.98x on a book value of ₹423.46 per share as of Mar 2026. Solomo computes return on equity of 15.96% and return on capital employed of 15.64% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 31.21x
- Industry P/E
- 36.41x
- P/B
- 4.98x
- EPS (TTM)
- ₹67.58
- Book value / share
- ₹423.46
- ROE
- 15.96%
- ROCE
- 15.64%
- ROA
- 8.48%
- Debt / equity
- 0.54x
- Dividend yield
- 0.33%
- EBITDA margin
- 31.77%
- 52-week range
- ₹1,250.95 – ₹2,347.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Hester Biosciences Ltd (HESTERBIO) reported revenue of ₹333 crore, net profit of ₹57 crore and earnings per share of ₹65.41. That compares with revenue of ₹311 crore and net profit of ₹29 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹100 crore and net profit ₹17 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 235 | 266 | 305 | 311 | 333 |
| Net profit (₹ cr) | 39 | 28 | 21 | 29 | 57 |
| EPS (₹) | 46.22 | 31.3 | 22.21 | 32.31 | 65.41 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.84% | 6.98% | 4.77% | 6.91% |
| Profit growth | 8.53% | 5.48% | 17.23% | 99.38% |
| Stock price CAGR | 13% | 0% | 12% | 31% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 53.73% of Hester Biosciences Ltd (HESTERBIO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.31% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹1,794 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Kuntal Hasmukhlal Shah 3.17%, Manish Jain 2.88%, Darshna Dinesh Kapadia 1.81%, Sandeep Shantilal Gala 1.3%, Vinay Shah 1.28%, Manish Jain (HUF) 1.23%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 53.73% | - | 0.31% | 0% | 46.27% |
| Mar 2026 | 53.73% | - | 0.38% | 0% | 46.27% |
| Dec 2025 | 53.73% | - | 0.51% | 0.01% | 46.27% |
| Sep 2025 | 53.73% | - | 0.53% | 0% | 46.27% |
| Jun 2025 | 53.73% | - | 0.52% | 0.02% | 46.27% |
| Mar 2025 | 53.73% | - | 0.87% | 0.02% | 46.27% |
| Dec 2024 | 53.73% | - | 0.59% | 0.02% | 46.27% |
| Sep 2024 | 53.73% | - | 0.61% | 0.02% | 46.27% |